102 related articles for article (PubMed ID: 31948126)
1. Phase I Study of a B Cell-Based and Monocyte-Based Immunotherapeutic Vaccine, BVAC-C in Human Papillomavirus Type 16- or 18-Positive Recurrent Cervical Cancer.
Choi CH; Choi HJ; Lee JW; Kang ES; Cho D; Park BK; Kim YM; Kim DY; Seo H; Park M; Kim W; Choi KY; Oh T; Kang CY; Kim BG
J Clin Med; 2020 Jan; 9(1):. PubMed ID: 31948126
[No Abstract] [Full Text] [Related]
2. Efficacy and safety of BVAC-C in HPV type 16- or 18-positive cervical carcinoma who failed 1st platinum-based chemotherapy: a phase I/IIa study.
Choi CH; Lee JW; Bae DS; Kang ES; Cho D; Kim YM; Kim K; Kim JW; Kim HS; Kim YT; Lee JY; Lim MC; Oh T; Song B; Jeon I; Park M; Kim WH; Kang CY; Kim BG
Front Immunol; 2024; 15():1371353. PubMed ID: 38605958
[TBL] [Abstract][Full Text] [Related]
3. First-in-Human Phase 1 Study of a B Cell- and Monocyte-Based Immunotherapeutic Vaccine against HER2-Positive Advanced Gastric Cancer.
Jung M; Lee JB; Kim HS; Kwon WS; Kim HO; Kim S; Park M; Kim W; Choi KY; Oh T; Kang CY; Chung HC; Rha SY
Cancer Res Treat; 2024 Jan; 56(1):208-218. PubMed ID: 37402409
[TBL] [Abstract][Full Text] [Related]
4. Phase II Trial of MEDI0457 and Durvalumab for Patients With Recurrent/Metastatic Human Papillomavirus-Associated Cancers.
Morris VK; Jazaeri A; Westin SN; Pettaway C; George S; Huey RW; Grinsfelder M; Shafer A; Johnson B; Vining D; Guo M; Fellman B; Frumovitz M
Oncologist; 2023 Jul; 28(7):618-623. PubMed ID: 37104874
[TBL] [Abstract][Full Text] [Related]
5. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities.
Santin AD; Bellone S; Palmieri M; Ravaggi A; Romani C; Tassi R; Roman JJ; Burnett A; Pecorelli S; Cannon MJ
Gynecol Oncol; 2006 Mar; 100(3):469-78. PubMed ID: 16249018
[TBL] [Abstract][Full Text] [Related]
6. A phase II trial of interleukin-12 in patients with advanced cervical cancer: clinical and immunologic correlates. Eastern Cooperative Oncology Group study E1E96.
Wadler S; Levy D; Frederickson HL; Falkson CI; Wang Y; Weller E; Burk R; Ho G; Kadish AS;
Gynecol Oncol; 2004 Mar; 92(3):957-64. PubMed ID: 14984966
[TBL] [Abstract][Full Text] [Related]
7. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity.
Kenter GG; Welters MJ; Valentijn AR; Lowik MJ; Berends-van der Meer DM; Vloon AP; Drijfhout JW; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; van der Burg SH; Melief CJ
Clin Cancer Res; 2008 Jan; 14(1):169-77. PubMed ID: 18172268
[TBL] [Abstract][Full Text] [Related]
8. Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical Trial.
Massarelli E; William W; Johnson F; Kies M; Ferrarotto R; Guo M; Feng L; Lee JJ; Tran H; Kim YU; Haymaker C; Bernatchez C; Curran M; Zecchini Barrese T; Rodriguez Canales J; Wistuba I; Li L; Wang J; van der Burg SH; Melief CJ; Glisson B
JAMA Oncol; 2019 Jan; 5(1):67-73. PubMed ID: 30267032
[TBL] [Abstract][Full Text] [Related]
9. In vitro antigene therapy targeting HPV-16 E6 and E7 in cervical carcinoma.
Madrigal M; Janicek MF; Sevin BU; Perras J; Estape R; Peñalver M; Averette HE
Gynecol Oncol; 1997 Jan; 64(1):18-25. PubMed ID: 8995542
[TBL] [Abstract][Full Text] [Related]
10. Enhanced Immunogenicity of Engineered HER2 Antigens Potentiates Antitumor Immune Responses.
Jeon I; Lee JM; Shin KS; Kang T; Park MH; Seo H; Song B; Koh CH; Choi J; Shin YK; Kim BS; Kang CY
Vaccines (Basel); 2020 Jul; 8(3):. PubMed ID: 32707803
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial.
Neuzil KM; Canh DG; Thiem VD; Janmohamed A; Huong VM; Tang Y; Diep NT; Tsu V; LaMontagne DS
JAMA; 2011 Apr; 305(14):1424-31. PubMed ID: 21486975
[TBL] [Abstract][Full Text] [Related]
12. Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus-Related Cervical Carcinoma.
Lheureux S; Butler MO; Clarke B; Cristea MC; Martin LP; Tonkin K; Fleming GF; Tinker AV; Hirte HW; Tsoref D; Mackay H; Dhani NC; Ghatage P; Weberpals J; Welch S; Pham NA; Motta V; Sotov V; Wang L; Karakasis K; Udagani S; Kamel-Reid S; Streicher HZ; Shaw P; Oza AM
JAMA Oncol; 2018 Jul; 4(7):e173776. PubMed ID: 29145543
[TBL] [Abstract][Full Text] [Related]
13. Radiation-enhanced expression of E6/E7 transforming oncogenes of human papillomavirus-16 in human cervical carcinoma.
Santin AD; Hermonat PL; Ravaggi A; Chiriva-Internati M; Pecorelli S; Parham GP
Cancer; 1998 Dec; 83(11):2346-52. PubMed ID: 9840534
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of human papillomavirus type 16 oncoproteins enhances hypoxia-inducible factor 1 alpha protein accumulation and vascular endothelial growth factor expression in human cervical carcinoma cells.
Tang X; Zhang Q; Nishitani J; Brown J; Shi S; Le AD
Clin Cancer Res; 2007 May; 13(9):2568-76. PubMed ID: 17473185
[TBL] [Abstract][Full Text] [Related]
15. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cell-based tumor vaccine for cervical cancer I: in vitro stimulation with recombinant protein-pulsed dendritic cells induces specific T cells to HPV16 E7 or HPV18 E7.
Nonn M; Schinz M; Zumbach K; Pawlita M; Schneider A; Dürst M; Kaufmann AM
J Cancer Res Clin Oncol; 2003 Sep; 129(9):511-20. PubMed ID: 12905010
[TBL] [Abstract][Full Text] [Related]
17. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer.
Borysiewicz LK; Fiander A; Nimako M; Man S; Wilkinson GW; Westmoreland D; Evans AS; Adams M; Stacey SN; Boursnell ME; Rutherford E; Hickling JK; Inglis SC
Lancet; 1996 Jun; 347(9014):1523-7. PubMed ID: 8684105
[TBL] [Abstract][Full Text] [Related]
18. Identification and characterization of enhancer agonist human cytotoxic T-cell epitopes of the human papillomavirus type 16 (HPV16) E6/E7.
Tsang KY; Fantini M; Fernando RI; Palena C; David JM; Hodge JW; Gabitzsch ES; Jones FR; Schlom J
Vaccine; 2017 May; 35(19):2605-2611. PubMed ID: 28389098
[TBL] [Abstract][Full Text] [Related]
19. Antisense targeting human papillomavirus type 16 E6 and E7 genes contributes to apoptosis and senescence in SiHa cervical carcinoma cells.
Sima N; Wang S; Wang W; Kong D; Xu Q; Tian X; Luo A; Zhou J; Xu G; Meng L; Lu Y; Ma D
Gynecol Oncol; 2007 Aug; 106(2):299-304. PubMed ID: 17586029
[TBL] [Abstract][Full Text] [Related]
20. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
Friedlander M; Meniawy T; Markman B; Mileshkin L; Harnett P; Millward M; Lundy J; Freimund A; Norris C; Mu S; Wu J; Paton V; Gao B
Lancet Oncol; 2019 Sep; 20(9):1306-1315. PubMed ID: 31378459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
